Search

Displaying results 2621 - 2630 of 9325 in total
  1. Drug

    Posaconazole

    go.drugbank.com/drugs/DB01263
    ApprovedInvestigationalVet approved

    Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.

    Products: NOXAFIL ® TABLETAS RECUBIERTAS DE LIBERACIÓN RETARDADA
  2. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. … [A225721,A225741] Tirbanibulin blocks the molecular pathways that promote the proliferation, survival, and metastasis of malignant cells.

  3. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    In January 2005, the U.S. … and oxygen to portions of the brain, for which phase III trials are currently being conducted.

  4. Drug

    Desoxyribonuclease

    go.drugbank.com/drugs/DB09551
    ApprovedInvestigational

    The enzyme's cofactor is reported to be magnesium (or manganese) ions, although the optimal concentration of the ion is independent of the enzyme concentration [A31251]. … The mechanism of action of the enzyme involves the splitting of thymus nucleic acid into fragments approaching the size of tetranucleotides without the release of free phosphoric acid.

  5. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    [A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib]. … when compared to [crizotinib].

  6. Drug

    Benznidazole

    go.drugbank.com/drugs/DB11989
    ApprovedInvestigational

    [L939] It is the first treatment made available in the United States for Chagas disease. … Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.

  7. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Therefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative

  8. Drug

    Glycerol phenylbutyrate

    go.drugbank.com/drugs/DB08909
    ApprovedInvestigational

    Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.

  9. Drug

    Omapatrilat

    go.drugbank.com/drugs/DB00886
    Experimental

    This drug from BMS was not approved by the FDA due to angioedema safety concerns. … The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling.

    Categories: Agents Acting on the Renin-Angiotensin System
  10. Drug

    CX-051869

    go.drugbank.com/drugs/DB31656
    Approved

    It is the active ingredient of the 2025-2026 formulation of Moderna's Spikevax vaccine.[L40074] … CX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1.